重药控股参股公司药友制药与辉瑞签署许可协议

Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has granted Pfizer exclusive rights to develop, use, produce, and commercialize the oral small molecule GLP-1 receptor agonist YP05002 and related products globally for various indications [1] Group 1 - Zhongyao Holdings holds a 38.67% stake in Yaoyou Pharmaceutical, which is the company developing YP05002 [1] - Yaoyou Pharmaceutical will receive a non-refundable upfront payment of $150 million and up to $350 million in milestone payments based on clinical and commercialization progress of the licensed product [1] - YP05002 is designed to treat type 2 diabetes, obesity, and related diseases by activating GLP-1 receptors to enhance insulin secretion and reduce glucagon secretion, among other mechanisms [1] Group 2 - Potential indications for YP05002 include long-term weight management, type 2 diabetes, and metabolic dysfunction-related fatty liver disease [1]